Figure 3.

FVIII and FIX therapeutic agents recently approved or in late-phase clinical development. Approved agents are presented with their trademarked names as TM. Agents in the late-phase trials discussed in this review are indicated by their clinical names. Fc fusion and albumin fusion denoted by Fc and FP. Human-cl rh indicates human cell line recombinant human. EHL, extended half-life. Adapted from Impact Education, LLC/National Hemophilia Foundation/Postgraduate Institute for Medicine with permission.⁴³